Here are some investment ideas from market experts for Daily Update Subscribe now https://www.facebook.com/ripplesadvisorypvtltd
Latest quarterly numbers from Sun Pharma and Tech Mahindra have come as a shocker for investors. Both companies belong to sectors currently experiencing pain and in the midst of a major overhaul.
Sun Pharma
Its US business (contributing to nearly 48 percent of total revenue historically) declined sharply by USD 127 million sequentially due to market share loss in Benicar AG and pricing pressure in gGleevec.
No comments:
Post a Comment